SODIUM IODIDE I-131 - Generic Drug Details

What are the generic sources for sodium iodide i-131 and what is the scope of patent protection?

Sodium iodide i-131 is the generic ingredient in three branded drugs marketed by Bracco, CIS, Curium, Jubilant, and Intl Isotopes, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

There are three drug master file entries for sodium iodide i-131. Two suppliers are listed for this compound.

Summary for SODIUM IODIDE I-131

US Patents:	0
Tradenames:	3
Applicants:	5
NDAs:	7
Drug Master File Entries:	3
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	8
Clinical Trials:	18
Patent Applications:	129
What excipients (inactive ingredients) are in SODIUM IODIDE I-131?	SODIUM IODIDE I-131 excipients list
DailyMed Link:	SODIUM IODIDE I-131 at DailyMed

Recent Clinical Trials for SODIUM IODIDE I-131

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Health Network, Toronto	Phase 4
Stryker Endoscopy	Phase 4
Osaka University	Phase 1

See all SODIUM IODIDE I-131 clinical trials

Pharmacology for SODIUM IODIDE I-131

Drug Class	Radioactive Therapeutic Agent
Mechanism of Action	Radiopharmaceutical Activity

US Patents and Regulatory Information for SODIUM IODIDE I-131

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cis	SODIUM IODIDE I 131	sodium iodide i-131	SOLUTION;ORAL	017315-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Bracco	IODOTOPE	sodium iodide i-131	SOLUTION;ORAL	010929-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Cis	SODIUM IODIDE I 131	sodium iodide i-131	CAPSULE;ORAL	017316-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Jubilant	HICON	sodium iodide i-131	SOLUTION;ORAL	021305-007	Dec 5, 2011	AA	RX	Yes	Yes
Curium	SODIUM IODIDE I 131	sodium iodide i-131	CAPSULE;ORAL	016515-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Bracco	IODOTOPE	sodium iodide i-131	CAPSULE;ORAL	010929-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Curium	SODIUM IODIDE I 131	sodium iodide i-131	CAPSULE;ORAL	016517-002	Approved Prior to Jan 1, 1982		DISCN	No	No

SODIUM IODIDE I-131 Market Analysis and Financial Projection Experimental

Sodium Iodide I-131: Market Dynamics and Financial Trajectory

Introduction

Sodium Iodide I-131, a radioactive isotope of iodine, is a crucial component in various medical applications, particularly in nuclear medicine. This article delves into the market dynamics and financial trajectory of Sodium Iodide I-131, highlighting its growth drivers, market size, and future projections.

Market Size and Growth Projections

The global Sodium Iodide market, which includes Sodium Iodide I-131, is anticipated to experience significant growth. By 2033, the Sodium Iodide market is expected to reach approximately USD 622.7 million, up from USD 341.2 million in 2023, growing at a Compound Annual Growth Rate (CAGR) of 6.2% during the forecast period from 2024 to 2033[1].

Key Drivers of Growth

Growing Demand in Medical Applications

The increasing use of Sodium Iodide I-131 in medical applications is a primary driver for the market. It is widely used in diagnostic imaging and therapeutic treatments, particularly for thyroid conditions such as hyperthyroidism and certain types of thyroid cancer. The demand for non-invasive diagnostic imaging techniques has risen significantly, further boosting the use of Sodium Iodide I-131[1].

Advancements in Medical Imaging Technologies

Advancements in medical imaging technologies, including molecular imaging techniques, are expected to enhance the role of Sodium Iodide I-131 in radiopharmaceuticals. This technological progress opens new growth avenues for the market[1].

Government Support and Healthcare Infrastructure

Government initiatives and investments in healthcare infrastructure also play a critical role. For instance, the U.S. government allocated USD 4.5 billion to nuclear medicine research in 2021, which indirectly benefits the Sodium Iodide market. Similarly, China's commitment to enhancing healthcare infrastructure drives the adoption of advanced imaging technologies that utilize Sodium Iodide I-131[1].

Applications and End-Use Segments

Medical Imaging

Sodium Iodide I-131 dominates the medical imaging segment, capturing a significant share of the market. It is used in the performance of radioactive iodide (RAI) uptake tests to evaluate thyroid function and in localizing metastases associated with thyroid malignancies[2].

Pharmaceutical Industry

The pharmaceutical industry is the largest end-use segment for Sodium Iodide I-131, accounting for approximately 56.4% of the market share. This is due to its extensive use in radiopharmaceuticals and other therapeutic applications[1].

Geographical Market Dynamics

Regional Growth

The Asia-Pacific region (APAC) is a significant market for Sodium Iodide I-131, driven by improving healthcare infrastructure and increasing demand for diagnostic and therapeutic solutions. Countries like Japan and India are expected to exhibit high demand, with CAGRs of 6.9% and 7.1%, respectively, through 2034[4].

Regulatory Environment

The regulatory environment plays a crucial role in shaping the market dynamics of Sodium Iodide I-131. Regulations governing the use of radioactive materials, such as those set by the FDA, ensure safety and compliance. For example, Sodium Iodide I-131 is contraindicated for use in pregnant women due to the potential harm it can cause to the fetal thyroid gland[2].

Health and Wellness Trends

Health and wellness trends, including the increasing demand for iodine supplements, are also driving the growth of the Sodium Iodide market. Consumers' preference for clean label products and natural sources of iodine is influencing product formulation and marketing strategies[4].

Financial Projections and Market Value

Current Market Value

The Sodium Iodide market, which includes Sodium Iodide I-131, was valued at approximately USD 341.2 million in 2023[1].

Future Projections

By 2033, the market is projected to reach USD 622.7 million, growing at a CAGR of 6.2% during the forecast period. This growth is driven by the increasing demand in medical applications, advancements in medical imaging technologies, and government support for healthcare infrastructure[1].

Impact on Thyroid Cancer Treatment

Thyroid Cancer Drug Market

The global thyroid cancer drug market, which includes treatments using Sodium Iodide I-131, is expected to grow significantly. This market was valued at USD 712.56 million in 2022 and is predicted to reach USD 2,505.56 million by 2030, growing at a CAGR of 17.2% during the forecast period. Radioactive iodine (radioiodine) therapy, which uses Sodium Iodide I-131, is a key treatment for thyroid cancer[3].

Key Takeaways

• The Sodium Iodide market, including Sodium Iodide I-131, is expected to grow from USD 341.2 million in 2023 to USD 622.7 million by 2033 at a CAGR of 6.2%.
• The pharmaceutical industry dominates the end-use segment, capturing 56.4% of the market share.
• Medical imaging applications, particularly in thyroid diagnostics and therapy, drive the market.
• Government support and advancements in medical imaging technologies are significant growth drivers.
• The APAC region, including countries like Japan and India, is expected to exhibit high demand.

FAQs

What is the primary use of Sodium Iodide I-131 in medical applications?

Sodium Iodide I-131 is primarily used in diagnostic imaging and therapeutic treatments, especially for thyroid conditions such as hyperthyroidism and certain types of thyroid cancer.

How does the regulatory environment impact the Sodium Iodide I-131 market?

The regulatory environment ensures safety and compliance, with specific regulations governing the use of radioactive materials. For example, Sodium Iodide I-131 is contraindicated for use in pregnant women.

What are the key drivers of growth for the Sodium Iodide I-131 market?

Key drivers include the growing demand in medical applications, advancements in medical imaging technologies, and government support for healthcare infrastructure.

Which region is expected to exhibit high demand for Sodium Iodide I-131?

The Asia-Pacific region, particularly countries like Japan and India, is expected to exhibit high demand, driven by improving healthcare infrastructure and increasing demand for diagnostic and therapeutic solutions.

How does the Sodium Iodide I-131 market contribute to the thyroid cancer drug market?

Sodium Iodide I-131 is a key component in radioactive iodine (radioiodine) therapy, which is a significant treatment for thyroid cancer. The growing demand for effective thyroid cancer treatments drives the market for Sodium Iodide I-131.

Sources

1. Market.us: Sodium Iodide Market Size, Share | CAGR of 6.2%
2. FDA: Sodium Iodide I 131 Capsules USP Diagnostic - Oral
3. Data Bridge Market Research: Global Thyroid Cancer Drug Market Size, Share & Revenue Analysis By 2030
4. Future Market Insights: Sodium Iodide Market Share, Trends & Forecast by 2034
5. LSU Repository: Evaluating Feline Release Criteria Following Iodine-131 Therapy